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Abstract
Introduction: Multiple myeloma is a haematologic malignancy 
characterised by the proliferation of plasma cells and typically presents 
with lesions in bone, known as plasmacytomas. Through haematogenous 
spread, extramedullary plasmacytomas can develop in soft tissue in any 
location of the body. This case report describes a patient with multiple 
myeloma who presented with an extramedullary plasmacytoma on his 
maxillary gingiva and provides an updated review on the classification and 
characterisation of extramedullary plasmacytomas of the oral cavity.
Case Description: A 53-year-old male with a known diagnosis of multiple 
myeloma was referred to our clinic for evaluation of a gingival nodule, 
which was tender to palpation and had been present for a month. Clinical 
examination revealed a 1.5  cm violaceous, red nodule of the maxillary 
buccal attached gingiva, which did not blanch on palpation. He had a similar 
1 cm, smooth, red nodule of his cutaneous skin on his left arm. Radiographic 
examination was within normal limits without evidence of dental or bony 
pathology. An incisional biopsy revealed the diagnosis of plasmacytoma, 
indicating relapse and progression of the patient’s multiple myeloma. 
Practical Implications: Multiple myeloma can present in the oral cavity 
either as intrabony plasmacytomas, paraskeletal plasmacytomas or 
extramedullary plasmacytomas in the soft tissue. Extramedullary disease 
representative of haematogenous spread is concerning for high-risk 
disease with a poor risk prognosis.
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Introduction
Multiple myeloma is a haematologic malignancy 
characterised by the proliferation of clonal plasma 
cells and represents 2% of all cancers and 19% of 
haematologic malignancies in the United States.[1] 
While the condition most commonly presents with 
multiple lytic lesions in bone, plasma cell neoplasms 
can also present as a solitary lesion, either in bone, 
known as a solitary plasmacytoma, or in soft 
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tissue, known as an extramedullary plasmacytoma. 
Extramedullary plasmacytomas have recently been 
classified as being true extramedullary lesions that 
are completely in soft tissue, or paraskeletal, with 
evidence of soft-tissue tumour masses developing 
from underlying bony lesions.[2] Extramedullary 
lesions have been documented in nearly every 
organ and tissue of the body. They can represent 
a solitary lesion that will not necessarily be 
associated with or progress into multiple myeloma 
or can be a sign of progressive disease with high-
risk cytogenetics and resistance to therapy.[3,4] 
We herein present a case of an extramedullary 
plasmacytoma presenting as a gingival nodule in 
the oral cavity and provide a review of the literature 
of the variable presentations of extramedullary 
plasmacytomas in the oral cavity using the most 
recent classification scheme of plasmacytomas.
Case Description
A 53-year-old male was referred to our clinic by 
his oncologist for evaluation of a nodule on his 
maxillary gingiva. He reported that the nodule had 
been present for approximately 1 month and was 
tender to the touch and on tooth brushing, with 
a pain intensity of 2/10. He also noticed a similar 
nodule growing on the skin of his left arm within 
the past month. His medical history was significant 
for kappa light chain multiple myeloma, which 
was diagnosed 7 years before the consult. He had 
undergone extensive prior treatment, including an 
autologous stem cell transplant 6 years prior, which 
was complicated by progressive disease and then 
treated with salvage chemotherapy followed by a 
reduced intensity conditioning allogeneic stem cell 
transplant 2 years before the visit. Due to progressive 
disease, he was then treated with panobinostat, 
bortezomib and dexamethasone, which was 
discontinued 1 month before our consultation due 
to the development of pneumonia secondary to 
immunosuppression, as well as progressive disease.
Examination revealed a 1.5 cm diameter nodule on 
the maxillary gingiva on the buccal aspect of right side 
maxillary lateral and central incisors [Figure 1a]. The 
lesion was smooth-surfaced and violaceous in colour, 
with a vascular appearance with red capillaries visible 
on the surface. It was firm, non-pulsatile and did not 
blanch when compressed. Radiographic examination 
with a full mouth series of dental radiographs showed 
no periapical radiolucencies of the adjacent teeth 
and no evidence of bony pathology. The rest of the 
examination was within normal limits in the head and 
neck; however, he had a similar smooth-surfaced 
cutaneous, red nodule measuring 1.5 cm in diameter 
on the skin of the left arm [Figure 1b]. The differential 
diagnosis included extramedullary plasmacytoma, 
pyogenic granuloma, peripheral giant cell granuloma, 
peripheral ossifying fibroma, vascular tumour 
(e.g., Kaposi sarcoma) and vascular malformation.
Diagnosis and management
Incisional biopsy of the oral lesion confirmed 
the definitive diagnosis of an extramedullary 
plasmacytoma. Given his refractory multiple 
myeloma with now extramedullary involvement, 
the patient received palliative radiation for the 
extramedullary plasmacytomas (20 Gray units 
administrated in five fractions). For his generalised 
progression of multiple myeloma, he was enrolled 
in a clinical trial of daratumumab, a monoclonal 
antibody that targets CD38 proteins expressed 
on myeloma cells; however, the patient continued 
to have progressive disease and passed away 
4 months after the consultation visit.
Discussion
In this case, a patient with progressive multiple 
myeloma known to be resistant to multiple lines of 
therapy presented with a gingival nodule that was 
Figure  1: A  53-year-old male with (a) violaceous-red 
nodule of the maxillary buccal gingiva of the right side 
maxillary lateral and central incisors and (b) a 1 cm, red, 
smooth-surfaced nodule of the anterior (flexor) surface 
of the arm near the elbow
a b
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biopsy proven to be an extramedullary plasmacytoma. 
Soft-tissue extramedullary plasmacytomas such as 
this are proposed to arise from the haematogenous 
spread of the neoplastic plasma cells. Incidence 
of extramedullary plasmacytomas (excluding 
paraskeletal plasmacytomas) ranges from 1.7 to 
4.5% at the time of diagnosis, but in patients with 
progressive disease and relapse has an incidence of 
up to 10%.[2] Lesions most commonly present in the 
skin, liver pleura, breast, lymph nodes and central 
nervous system. When visible, lesions most commonly 
present as nodules that appear highly vascularised 
with a red-purple appearance, as seen in both the oral 
and cutaneous nodules in the present case.
In the oral cavity, case reports exist describing 
both paraskeletal extramedullary lesions and 
true extramedullary lesions arising in soft tissue 
without evidence of radiographic involvement. In 
paraskeletal oral lesions, patients will present with 
a large mass of the maxillary or mandibular alveolar 
ridge, with the overlying gingiva and mucosa 
ranging from pink and healthy in appearance to 
erythematous, ulcerated or necrotic.[5-7] For true 
extramedullary lesions without underlying bony 
involvement, lesions have been reported in the 
gingiva, buccal mucosa, labial mucosa, tongue and 
uvula.[8,9] One report described an extramedullary 
plasmacytoma that presented as a flat, non-tender 
erythematous macule, or erythroplakia, of the soft 
palate.[10] While plasmacytomas in the buccal and 
labial mucosa, tongue and uvula are clearly in soft 
tissue and represent the haematogenous spread 
of plasma cells, the gingiva represents a site of soft 
tissue that is attached to the underlying alveolar 
bone of the maxilla or mandible. In the case of 
gingival plasmacytomas, distinguishing between 
a paraskeletal and extramedullary plasmacytoma 
based on the most recent definitions is challenging, 
and a thorough radiographic examination with a 
computerised tomography (CT) scan would be 
needed to definitively determine whether there 
is bony involvement. However, such imaging is 
not always necessary from a clinical standpoint – 
diagnosis is typically confirmed with an incisional 
biopsy in the oral cavity. In lesions where access for 
biopsy is not possible, magnetic resonance imaging 
or fluorodeoxyglucose (FDG)-positron emission 
tomography/CT (FDG-PET/CT) is recommended 
to assess the extent of soft-tissue disease.[2]
In this case report, the patient had progression 
of his multiple myeloma despite multiple lines of 
therapy. The presence of multiple extramedullary 
plasmacytomas of the skin and oral cavity, revealing 
the haematogenous spread of clonal plasma cells, 
represented relapse of his disease and an overall 
poor prognosis. For patients with relapse of 
multiple myeloma presenting with extramedullary 
disease, recommendations include consideration 
of an allogeneic stem cell transplant or salvage 
chemotherapy with a lymphoma-like regimen such 
as cisplatin, doxorubicin, cyclophosphamide and 
etoposide (PACE). Alternative treatment options 
include regimens containing novel therapeutics, 
such as carfilzomib or selinexor. In refractory, 
relapsed patients, autologous chimeric antigen 
receptor T-cell treatment is another therapeutic 
option that utilises a targeted approach to attack 
malignant plasma cells by modifying T-cells to 
selectively target the B-cell maturation antigen 
present on the plasmacytoma surface.[11,12] In 
our case, because the patient had developed 
resistance to many of the above treatments, 
he instead received radiation therapy to the 
extramedullary lesions and enrolled in a clinical 
trial with daratumumab.
In conclusion, this case report describes an 
extramedullary plasmacytoma presenting as a 
violaceous nodule on the maxillary buccal gingiva 
without radiographic evidence of underlying 
bony involvement in a 53-year-old man with 
progressive, treatment-resistant multiple myeloma. 
Extramedullary plasmacytomas in the oral cavity 
have been documented as masquerading as 
benign-appearing, homogeneous pink or red 
nodules in the gingiva, buccal or labial mucosa and 
tongue. Patients who present with an extramedullary 
plasmacytoma as the heralding lesion of multiple 
myeloma should be considered as having high-risk 
disease, whereas similarly patients with a known 
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diagnosis of multiple myeloma presenting with an 
extramedullary plasmacytoma at relapse have an 
extremely poor prognosis.
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